タイトル:

出版社:

ISBN:

著者:

キーワード:

カテゴリー:

発行年:

～

検索条件をクリア

書籍詳細

未契約

書籍名	産婦人科診療今日の話題―2012
出版社	永井書店
発行日	2012-02-20
著者	玉舎輝彦(著)
ISBN	9784815918941
ページ数	111
版刷巻号	第1版
分野	臨床医学：外科産婦人科学
閲覧制限	未契約

本書では，産婦人科臨床上の普遍した指針について，著者が内外の今日まで蓄積された文献を渉猟し，その指針として改変せざるをえない事項を明らかにするとともに，わかりやすく解説しながら今日の産婦人科学の到達点を見据える．　産婦人科医には，産婦人科臨床での重要な指針と糧を与えてくれるとともに，看護師にも手に取りやすくわかりやすい内容となっている．座右の書としても格好の好著である．

目次

表紙
閲覧
巻頭言
閲覧
目次
閲覧
I. 産科
P.1閲覧
- 1. 帝王切開術をめぐる話題
- 2. 感染症における病原微生物の内分泌学的役割
II. 婦人科
P.17閲覧
- A. 婦人科腫瘍をめぐる話題
- B. 日本女性の乳がん・卵巣がん・子宮内膜症リスクの増加の可能性に対する先進諸国の疫学からの提言
- C. 内分泌
索引
P.97閲覧
奥付
閲覧

参考文献

I. 産科

P.11 掲載の参考文献

1) Rotus MA, Harbermann S, Lergur M:Cesarean Scar Ectopic pregnancies. Etiology, Diag-nosis and Management. Obstet Gynecol 107 : 1373-1381, 2005.

2) Jaukabic D, Hillby K, Woelfer B, et al : First trimester diagnosis and management of pregnancies implanted into the loweruterine cesarean section scar. Ultra sound Obstet Gynecol 21 : 220-227, 2002.

3) Fystra DL : Ectopic pregnancy within a cesarean scar : areview. Obstet Gynecol Surv 57 : 537-543, 2002.

4) Weimin W, Wenging L : Effect of early pregnancy on a previous lower segment cesarean section scar. Int J Gynecol Obstet 77 : 201-207, 2002.

5) Vial Y, Petignat P, Holdfeld P : Pregnancy in a sesarean section scar : a case report. Int J Gynecol Obstet 57 : 537-543, 2002.

6) Chou MM, Hwang JI, Tseng JJ, et al : Cesarean scar pregnancy : quantitative assessment of uterine neovascularization with 3-dimensional with uterine artery embolization. Am J Obstet Gynecol 190 : 866-868, 2004.
pubmed

7) Chung J, Seow KM, Cheng WC, et al : Concervative treatment of ectopic pregnancy in a cesarean section scar. B J Obstet Gynecol 110 : 869-870, 1992.

8) Schiff E, Shaler E, Bustan M, et al : Pharmacokinetics of methiotrexate after local tubal injection for conservative treatment of ectopic pregnancy. Fertil Steril 57 : 88-90, 1992.

9) Porter M, Battachaya S, vann Teijlingen E, Templeton A, for the Reproductive outcome Following Cesarean Section (ROCS) Collaborative Group : Human Reprod 109 : 597-605, 2003.

10) Thomas J, Paranjothy S, Ryal College of Obstetricians and Gynecologists Clinical Effective-ness unit : National Sentinel Caesarean Audit Report. RCOG Press, London, UK, 2001.

11) Bowley S, Cockbum J :The unfacst of request;caesarean section. Br J Obstet Gynecol 109:597-605, 2002.

12) Heminki E, Hoffman HJ, Graubard BI, et al:Cesarean section and subsequent fertility:results from the 1982 National Survey of Family Growth. Fertile Steril 43:520-528, 1985.

13) van Roosmalen J:Safe motherhood;cesarean section or symphysiotomy ? Am J Obstet Gynecol 163 : 1-4, 1996.
pubmed

14) World Health Organization:Essential obstetric functions at first referral level. Geneva:Word Health Organization, 1986.

15) van Roosmalen J : Symphysiotomy as an altemative to cesarean section. Int J Gynecol Obstet 25 : 451-458, 1987.

16) Gebbie DAM : Symphysiotomy. Trop dort 4 : 69-75, 1974.

17) Jams JD, Goldenberg RL, Mercer BM, et al:The length of the cervix and the risk of sponta-neous premature delivery. N Engl J Med 334 : 567-572, 1996.

18) Berghella V, Odido AO, To MS, et al:Cerclage for Short Cervix on Ultrasonography. Obstet Gynecol 106 : 181-189, 2005.

19) Jams JD, Johnson FF, Soneck J, et al:Cervical incompetenceon obstetrical outcome in twin as a continuum a study of Ultrasonographic cervical length. Am J Obstet Gynecol 12 : 318-322, 2001.

20) Mays J, Figueroa R, Shah J, et al:Amniocentesis for serection befor rescue cerclage. Am J Obstet Gynecol 95 : 652-655, 2000.

21) Mercer BM : Preterm premature rupture of membranes : dignosis and management. Clinics in Perinatology 31 : 765-782, 2004.

22) ACOG PRACTICE BULETIN : Premature nlpture of membranes. Obstet Gynecol 109 : 1007-1019, 2007.

23) 岩谷壮太 ,中尾秀人 : 新生児側から見たPROMにおける分娩のタイミング. 産婦治療 102 : 349-354, 2011.

P.13 掲載の参考文献

1）Selo-Ojeme PO, Onwude JL, et al : Autotransfusion for ruptured ectopic pregnancy. Int J Gynecol Obstet 80 : 103-110, 2003.

P.16 掲載の参考文献

1) Lyte M : The role of microbial endocrinology in infectious disiese. Endocrinol 137 : 343-345, 1993.
pubmed

2）Lenard J : Trends in Biochemical. Sciences 17 : 147-150, 1992.
pubmed

3) Shapiro AJM, et al : J Pham 87 : 127-132, 1983.

4) Miller VL, et al : Infection and Immunity 50 : 1242-1248, 1988.

5) Gaudin C, et al : J Archium Imnumologieae et Therapiae Experimentalis 20 : 951-957, 1972.

6) Benedict CR, et al : J Med 47 : 1-20, 1978.

7) Jones SB, et al : Am J Physiol 245 : R470-R477, 1988.

8) Gruchow HW, et al : J Hum Stress 5 : 11-17, 1979.

9) Powell BL, et al : Inf Immun 40 : 478-485, 1983.

10) DeCastro SL, et al : Exp Parasit 64 : 368-375, 1991.

11) Smith TA : Biol Per Cambr Phyosoph Soc 46 : 201-204, 1971.

12) Ngarah A, et al : Scand J Urol Nephrol 11 : 219-224, 1997.

13) Parat R, et al : Science 254 : 430-432, 1991.

14) Peterson PK, et al : Rev Inf Dis 13 : 710-720, 1991.

II. 婦人科

P.23 掲載の参考文献

1) Covenns AL : Comentary A Critique of Surgical Cytoreduction in Advanced Ovarian Cancer. Gynecol Oncol 78 : 269-274, 2000.

2) Hacker NF : Controversial aspects of cytoreductive surgery in epithelial ovarian cancer. Baillieere's Clin Obstet Gynecol 3 : 49-57, 1989.

3) Goldie JH, Caldoman AJ : A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63 : 1727-1733, 1979.

4) van der Burg MEL, vanhent M, Byse M, et al:The effect of debulkingsurgery after induc-tion chemotherapy on the prognosis in advanced ovarian epithelial ovarian cancer. N Engl J Med 332 : 629-634, 1995.

5) Griffiths G, Parker LM, Fuller AF:Role of advanced ovarian cancer. Cancer Treat Rep 63 : 235-240, 1979.

6) Piver MS, Lele SB, Marchetti DL, et al:The impact of aggressive devulking Surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. J Cin Oncol 6 : 983-989, 1988.

7) Michel G, Delaco P, Castaigne D, et al:Extensive cytoreductive surgery in advanced ova-rian carcinoma. Eur J Gynecol Oncol 18 : 9-15, 1997.

8) Nguyen NH, Averette HE, Hoskins W, et al:National survey of ovarian carcinoma part IV;The impact of physician's specialty on patient survival. Cancer 72 : 3663-3670, 1993.

9) Hogberg T : Primary surgery in ovarian cancer : current opinions. Ann Med 27 : 95-100, 1955.

10) Hacer NF, Berek JS, Lagasse LD, et al:Primary cytoreductive surgery for epithelial ovarian carcinoma. Obstet Gynecol 61 : 413-420, 1983.

11) Eisenkop SM, Friedman RL, Wahg HJ : Complete cytoreductive surgery is feasible and maxi-mizes survival patients with advanced epithelial and survival ovarian cancer. Baillere's Clin Obstet Gynecol 61 : 413-420, 1983.

12) Jacob JH, Gesenson DM, Moris M, et al:Neoajuvant chemotherapy for advanced epithelial ovarian cancer. Gynecol Oncol 42 : 146 150, 1991.

13) Bockman YV, Vaokurov VL, Gulo E:The controversial second-look lapalotomy. Acta Obstet Gynecol Scand 155 (Suppl) : 7983, 1992.

14) Barber NRK : Ovarian cancer. Cancer Clin 36 : 149, 1986.

15) Zang R-Y, Zi Ting L, Tng NN : Secondary Cytoreductive Surgery for patients with relapsed epithelial ovarian carcinoma : Who benefits ? Cancer 100 : 1152-1161, 2004.

P.25 掲載の参考文献

1) Gehring PA, Van Le L, Fowler WC : The role of omentectomy during the surgical staging of uterine serous carcinoma. In J Gynecol Cancer 13 : 212-215, 2003.

2) Bergholt T, Eriksen L, Jacobsen M, et al:Prevalence and risk factors of adenomyosis at hysterectomy. Hum Reprod 11 : 2418-2421, 2001.
pubmed

3) Gehring PA, Croben PA, Fowler WC, et al:Non invasive papillary serous carcinoma of the endometrium. Obstet Gynecol 97 : 153-157, 2001.

4) Hendrickson M, Ross J, Eifelel P, et al:Uterine papillary serous carcinoma. Am J Surg Pathol 6 : 670-674, 1986.

1) Campagnutta E, et al:Surgical treatment of recurrent endometrial carcinoma. Cancer 100 : 89-96, 2004.
pubmed

P.26 掲載の参考文献

1) Bergholt T, Eriksen L, et al:Prevalence and risk factors of adenomyosis at hysterectomy. Hum Reprod 16 : 2418-2421, 2001.
pubmed

1) Narayan K : Arguments for a magnetic resonance imaging-assisted FIGO staging system for cervical cancer. Int J Gynecol Cancer 15 : 573-582, 2005.
pubmed

P.27 掲載の参考文献

1) Plante M, MC Penaud, et al:Vaginal radical trachelectomy:an oncologically safe fertility preserving surgery. An updated series of 72 cases review of the literature. Gynecol Oncol 94 : 614-623, 2004.

P.28 掲載の参考文献

1) Thompson JD : Hysterectomy. In : Thompson JD, Rock JA (editors), Telinde's Operative Gynecology, 7th ed, p663-738, Lippincott, Philadelphia, 1992.

2) Martinez CV, Civetta JM, et al:Bacteriuria in the catheterized surgical intensive care patient.bCrit Care Med 4 : 188-191, 1999.

3) Dunn JS, Shlay J, Forshner D:Are indwelling catheters necesaly for 24 hours after hystrectomy ? Am J Obstet Gynecol 189 : 435-437, 2003.

1) Horn J CE, Fischer CL, et al:Occult tumor cells in surgical specimens from cases of early cervical cancer treated by liposuction assisted nerve-sparing radical hystrectomy. Int J Gynecol Cancer 11 : 159-163, 2001.

P.30 掲載の参考文献

1) Shamlan S, Odunsi K, Deiscoli D, et al:Pelvic exenterations for gynecological malignancies:twenty-year experience at Roswell Park Cancer. Int J Gynecol Cancer 15 : 475-482, 2005.

2) Lopez MJ, Petros JG, Augustinos P:Development and evolution of elvic exenteration:his-torical notes. Semin Surgery Oncol 17 : 147-151, 1999.

3) Brunschwig A : Complete excision of pelvic evisceration in surgery. Surgery 30 : 76-94, 1951.

4) Hatch KD : Editorial : The role of operative laparoscopy to evaluate candidates for Pelvic exenteration. Gynecol Oncol 69 : 93, 1998.
pubmed

5) Plante M, Roy M : Operative laparoscopy prior to a pelvic exenteration in patients with recur-rent cervical cancer. Gynecol Oncol 69 : 94-99, 1998.

6) Kapstein SH, SchoneefuβG, Hoffmann SO, et al : pelvic exenteration : effects of surgery on quality of life and body image ; a prospective longitUdinal study. Gynecol Caner 66 : 495-500, 1997.

P.38 掲載の参考文献

1) 津熊秀明, 北川貴子, 花井采:癌罹患の動向-西暦2015年までの全国値推計-. 癌の臨床 38 : 1-10, 1992.

2) Zografos GC, PanouMP, Panou N : Comon risk factors and ovarian cancer:recent view. Int J Gynecol Cancer 14 : 721-740, 2004.

3) Lippman ME : Breast cancer. In Bunwald E, Fauci AS, Kasper DL, et al (eds), Harison`s Principles of Intemal Medicine, 15th edis, p572, McGrow-Hill, 2001.

4) Lambe M, Hsieh CC, Chan HW, et al:Parity age at first and last birth and risk of breast cancer. A population based study in Sweden. Breast Cancer Res Treat 38 : 305-311, 1995.

5) Hiatt AA, Fireman BH : Smoking, menopause, and breast cancer. J Natl Cancer Inst 76 : 833-838, 1986.

6) Ciaffarino F, Pelucchi C, Parazzini F, et al:Reproductive and hormonal factors and ovarian cancer. Ann Oncol 12 : 337-341, 2001.

7) Merrill RM, Lelinneth SF, Novill B, et al:Cancer risk associated with early and late maternal age at first birth. Gynecol Oncol 196 : 583-593, 2005.

8) Milligan RA, Pugh LC, Bronney YL, et al:Breast feeding dulation among low income women. J Midwifery women Health 45 : 246-252, 1992.

9) Titus-Emstoff, Prezzk L, Crramer DW, et al:Menstrual and reproductive factors in relation to ovarian cancer risk. Br J Cancer 84 : 714-721, 2001.

10) Tung KH, Goodman MT, Wu AH, et al:Reproductive factors and epithelial ovarian cancer risk by histologic type : a multiethienic case-control study. Am J Epidemiology 158 : 629-382, 2003.

11) Lemer-Geva L, Geva E, Lessing JB, et al : The possible association between in vitro fertilization treatments and cancer development. Int J Cancer 13 : 23-27, 2003.

12) Fischel S, Jackson P:Follicular stimulation for hightech pregnancies;are we playing it safe ? J Steroid Biochem 27 : 894-897, 1987.

13) Sutherland RL, Watts CKW, Hall RE, et al : Mechanism of growth inhibition by nonsteroidal antiestrogens in human breast cancer cells. J Steroid Biochem 27 : 894-897, 1987.

14) Terry DD, Miller AB, Roban TE : Cigarrett smoking and the risk of invasive epithelial ovarian cancer in prospective cohort study. Eur J Cancer 39 : 157-1164, 2000.

15) Schildkraut JM, Calingaert B, Marchbanks PA, et al : Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer-risk. J Natl Cancer Inst 94 : 297-304, 1999.

16) Riman T, Dickman PW, Milson S, et al:Hormon replacement therapy and the risk of invasive epithelial ovarian cancer in a riskfactors for Swedish women. J Natl Cancer Inst 95 : 363-373, 2002.

17) LaVecchia C, Negri E, Franceschi S, et al:Olive oil,other dietary fats, and the risk of breast cancer (Itary). Cancer Causes Control 6 : 545-550, 1995.

18) Dailing IR, Malone KE, Doody DR, et al:Association of regimens of homone replacement therapy to prognostic factors among women giagnosed with breast cancer aged 50-64 years. Cancer Epidemiol Prev 12 : 1175-1131, 2003.

19) Beral V:Million women study collaborators. Breast Cancer and hormone-replacement therapy in the million women study. Lancet 362 : 419-427, 2003.
pubmed

20) Sit AS, Modugno F, Weissfeld JL, et al:Hormone replacement therapy formulations and Risk of epithelial ovarian carcinoma. Gynecol Oncol 86 : 118-123, 2002.
pubmed

21) Eden J : Breast cancer. Estrogens and progestogens in clinical practice, By Fraser I, Jansen R, Lobo R, Whitehead M (eds), p737-744, Churchil-Livingstone, London, 1988.

22) Melin A, Sparen P, Person I, et al:Endometriosis and the risk of cancer with special emphasis of ovarian cancer. Hum Reprod 21 : 1237-1242, 2006.

23) ergqvist A : Extragenital endometriosis. A review. Eur J Surg 158 : 7-12, 1992.
pubmed

24) Sampson J : Endometrial carcinoma of the ovary. Arising in endometrial tissue in that organ. Arch Surgery 10 : 1-72, 1925.

25) Green A, Purdie D, Bain C, et al:Tubal sterilization,hysterectomy and the decreased risk of ovarian cancer. Int J Cancer 91 : 948-951, 1997.

25) Conttrou CM, Ness RB, Modugno F, et al:Endometriosis and its treatment with danazol or Luplon in relation to ovarian cancer. Clin Cancer Res 95 : 42-47, 2002.

26) Brinton LA, Gridley G, Caｒｒlstrom K, et al : Cancer risk after after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol 176 : 572-579, 1997.

27) Koninek V PR, et al : Endometriotie disease:the role of peritoneal fluid. Hum Reprod Update 4 : 741-751, 1997.

28) Moysich KB, Menezes RJ, Baker JA, et al:Environmental exposure to polychlorinated biphenils and breastcancer risk. Rev Environ Helth 17 : 263-277, 2002.

29) Calle EE, Frumkin H, Henry S, et al : Organochlorines and breast cancer risk. CA Cancer J Clin 52 : 301-309, 2002.

30) Jeffy BD, Cinornonas RB, Romaggnolo DF:Epigenetics of breast cancer risk. Polycyclic aromatichydrocarbons as risk factors. Environ Mol Mutagen 39 : 235-244, 2002.

30) Donna A, Crosignani P, Robutti F : Triazine berbicides and ovarian epithelial neoplasmas. Scand J Work Environ Health 15 : 47-53, 1989.

31) Gammon MD, Wolf MS, Neugut AI, et al : Environmental exposure to polychlorinated biphenils and breast cancer risk. CA Cancer J Clin 52 : 686-697, 2002.

32) Hansen J:Breast cancer risk among relatively youngwomen employed in solvent-using industries. Am J Ind Med 36 : 43-47, 1999.

33) Freedman DM, Domeci M, MC GIynn K:Sunlight and motality from breast, colon, prostate, and nonmelanoma skin cancer;a composite death certificate based case-controled study. Occup Environ Med 59 : 257-262, 2002.

34) Feychting T, Fororssen U, Rutqvist LE, et al:magnetic fields and breast cancer in Swedidish adults residing near high-voltage power lines. Epidemiology 9 : 392-397, 1998.

35) Weiderpass E, Pukkala E, Kaupinen T, et al : Breast cancer and occupational expousures in women in Finland. Am J Int Med 36 : 48-53, 1999.

36) Newcomer DM, New-comb PA, Potter DJ, et al : Postmenopausal estrogentherapy andrisk of breast cancer by histologic type (United States). Cancer Causes Control 14 : 225-223, 2003.

37) Petrelli JM, Calle EE, Rodorigeguez C, et al : Bodymass index, heit, and postmenopousal breast breast cancer mortality in a prospective cohort of US women. Cancer Causes Control 13 : 325-332, 2002.

38) Cui Y, Whiteman MK, Flaws J, et al:Body mass and postmenopousal breast cancer at diagnosis. Int J Cancer 98 : 279-283, 2002.

39) Borugian MJ, Sheps SB, Kim-Sing C : Waist-to Hip ratio and breast cancer motality. Am J Epidemiol 158 : 963-968, 2003.

40) Havie M, Hooper L, Howell AH:Central obesity and breast cancer risk:a systematic review. Obes Reev 4 : 157-173, 2003.

41) Shanonn J, Cook LS, Stanford JL : Dietary intake and risk of postmenopausal breast cancer (United States). Cancer Causes Control 14 : 19-27, 2003.

42) Potischman N, Coates RJ, Swanson CA, et al:Increased risk of eary-stage breast cancer related to consumption of sweetfoods amongwomen less than age 45 in the United States. Cancer Causes Control 13 : 937-946, 2002.

43) La Vecchia C, et al : olive oil, other diatory fats and the risk cancer [Itary]. Cancer Causes Control 6 : 545-550, 1995.
pubmed

44) Mattisson I, Wirfalt E, Johansson U, et al : Intakes of plantfoods, fiber and risk of breast cancer-a prospective study in the Malmo Diet and Cancer cohort. Br J Cancer 90 : 122-127, 2004.

45) Tavani A, Peludchi C, et al:n-3 poly unsaturated fatty acid in take and breast cancer incidence. Nutr Cancer 45 : 168-175, 2003.

46) Reynolds P, Hurley S, Goldberg DE, et al : Active smoking, household passive smoking, and breast : evidence from the Califormiateachers study. J Natl Cancer Inst 96 : 29-37, 2004.
pubmed

47) Tijonneland A, Christensen J, Thomsen BL, et al : Lifetime alcohol consumption and post-menopausal breast cancer rate in Denmark : a prospective cohort study. J Nutr 134 : 173-178, 2004.

48) Easton DF, Bishop DY, Ford D, et al:Gentic linkage analysis in familialbreast and ovarian cancer : results from214 families. Am J Hum Genet 52 : 678-701, 1992.

49) Ford D, Easton DF, Stratton M, et al:Genetic heterogeneity and penetrance analysis of BRCA 1 or BRCA 2 genes in breast cancer families. The breastcancer linkage consortium. Am J Hum Genet 72 : 1117-1170, 2003.

50) Lerman G, Narod S, Borney G, et al:BRCA1 testing infamilies with hereditary breast-ovarian cancer : A Prospective study of patient decision making and outcomes. JAMA [日本語版, 峠哲哉訳, 解説] 24 : 1885-1892, 1996.

P.44 掲載の参考文献

1) Mellin A, Spare' P, Persson I, et al : Endometriosis and the risk of cancer. Hum Reprod 31 : 1237-1243, 2006.

2) Modesiitt SC, Torlero-Luna G, Robinson JB, et al:Ovarian endometriosis-associated cancer. Obstet Gynecol 100 : 788-795, 2002.

3) 津熊秀明, 北川貴子, 花井采 : 癌罹患の動向-西暦2015年までの全国値推計-. 癌の臨床 38 : 1-10, 1992.

4) Eskenazi B, Warner ML : Epidemiology of endometriosis. Obstet Gynecol Clin North Am 124 : 235-258, 1997.

5) Bergqvist A : Extragenltal endometriosis : Areview. Eur J Surg 158 : 7-12, 2001.

6) Sampson J : Endometrial tissue in the ovary arising carcinoma of that organ. Arch Surg 10 : 1-72, 1925.

7) Stem RC, Dash R, Bently RC, et al : Malignancy in endomeniosis, Frequency and comparison of ovarian and extraovarian types. Int J Gynecol Pathol 20 : 133-139, 2001.

8) Brinton LA, Gridley G, Carlstrom K, et al:Fibrolytic factors in endometriotic tissue,endometrium, peritoneal fluid, and plasma from women with endometriosis and in endometrium and peritoneal fluid from healthy women. Fertil Steril 70 : 821-826, 1998.

9) Ness RB, Cramer DW, Goodman MT, et al : Infertility, fertility drugs, ovarian cancer:a pooled analysis of case-control studies. Am J Epidemiol 155 : 217-224, 2002.
pubmed

10) Ness RB, Cttreau C, Klapper J, et al : Factors related to inflamation of the ovarian epithelium and risk of ovarian cancer. Epidemiology 11 : 1111-1117, 2000.

11) Modugno F, Ness RB, Modugno F, et al:Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis. Am J Obstet Gynecol 191 : 733-740, 2004.
pubmed

12) Contreau CM, Ness RB, Modugno F, et al:Endometriosis and the treatment with danazol or Lupron in relation to ovarian cancer. Clin Cancer Res 9 : 5142 5244, 2003.

13) Brinton LA, Gridley G, Tbarron J, et al:Cancer risk after a hospital discharge of endometriosis. Am J Obstet Gynecol 196 ; 572-579, 1997.

14) Green A, Purdie D, Bain C, et al : Tubal sterilization, Hysterectomy decreased risk of ovarian cancer. Int J Cancer 71 : 948-951, 1997.
pubmed

15) Erzen M, Rakar S, Klancar B, et al:Endometriosis‐associated ovarian carcinoma [E-AOC]:entity distinct from other ovarian carcinomas as suggested by a nested case control study. Gynecol Oncol 83 : 1000-108, 2001.

16) Chiaffarino F, Parazzini F, LaVeechia C, et al : Mensｔrual and reproductive factors in relation to ovarian cancer risk. Ann Oncol 12 : 337-341, 2001.

17) Hankinson SE, Heuch I, Kuvale G : Reproductive factors and incidence of epithelial ovarian cancer risk. Cancer 76 : 284-290, 1995.

18) Titus-Emstoff L, Perez K, Cramer DW, et al : Menstrual and reproductive factors in relation to ovarian cancer risk. Br J Cancer 84 : 714-721, 2001.

19) Schldkraut JM, Calingaert B, Marchbanks PA, et al:Impact of progestin and estrogen potency oral contraceptive on ovarian cancer risk. J Natl Cancer Inst 94 : 32-38, 2002.

20) Riman T, Dickman PW, Nilsson S, et al : Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 94 : 497-504, 2002.
pubmed

21) Gambacciani M, Monteleone P, Sacco A, et al : Hoｒmone replacement therapy and endometrial ovarian carcinoma. Gynecol Oncol 86 : 118-123, 2002.

22) Koninkx PR, Kennedy SH, Barlow DH : Endometriotic disease : the role of peritoneal fluid. Hum Reprod Update 4 : 741-751, 1998.

23) Ganbacciani M, Mink PJ, Lubin JH, et al : Menopausal hormone replacement therapy and risk of ovarian cancer and colorectal cancer. Best Pract Res Clin Endocriｎol Metabo 17 : 139-140, 2002.

P.52 掲載の参考文献

1) Zografbs G, C Panou, M Panou : Comon riskfactors of breast and ovarian cancer : recent review. Int J Gynecol Cancer 14 : 721-740, 2004.

2) Bergqvist A : Extragenital endometriosis, A review. Eur J Surg 158 : 7-12, 1992.
pubmed

3) Sampson J : Endometrial carcinoma of the ovary arising in endometrial tissues in that organ. Arch Surg 10 : 1-72, 1925.

4) Auersperg K, Wong AST, Choi KC, et al:Ovarian Surface Epithelium:Biology Endocrinology,and Pathology. Endocrine Reviews 22 : 255-288, 2001.

5) Herbst AL : The epidemiology of ovarian carcinoma and the current status of tumor markers to detect disease. Am J Obstet Gynecol 170 : 1099-1105. 1994.
pubmed

6）Fathalla MF:Incessant ovulation a factor in ovarian cancer. Gynecol Oncol 66:3-9, 1997.

7) Ness RB, Cottreau C : Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 91 : 1459-1467, 1999.
pubmed

8) Scully RE:The pathogenesis of ovarian inclusion cysts and cystomas. Obstet Gynecol 49 (Suppl): S9-S15, 1976.

9) Scully RE:Early denovo ovarian cancer and cancer developing in benign ovarian lesions. Int J Gynecol Obstet 49 (Suppl) : 424-429, 1996.

10) CunatSe', Hoffmann P : Estrogens and epithelial cancer. Gynecol Oncol 94:25-32, 2004.
pubmed

11) Emons G, Ortmann O, Pahwa GS, et al : LH-RH agonists in the treatment of ovarian cance-Recent Results. Cancer Res 124 : 55-68, 1992.

12) Slotman BJ, Rao BR:Ovarian cancer, Etiology, diagnosis, surgery, radiotherapy, and chemotherapy, and endocrine therapy. Anticancer Res 8 : 411-434, 1988.

13) 玉舎輝彦 : 卵巣腫瘍とステロイドレセプター. 産と婦 11 : 1697-1701, 1982.

14) Pujol P, Rey JM, Nirde P, et al : Differential expression of estrogen receptor-alpha and-beta messenger RNAs as a potential marker of ovarian epithelial cells. Proc Natl Acad Sci USA 96 : 5722-5727, 1999.

15) Rao RB, Slothman BJ:Endocrine Factors in 10 nonepithelial ovarian cancer. Endcr Rev 12 : 14-26, 1991.

16) Hiller S, Anderson RA, Williams AR, et al:Expression of oestrogen receptor alpha and beta incultured human ovarian surface epithelial cells. Mol HUM Reprod 4 : 811-815, 1998.

17) Oug A, Mainees-Bandiera SL, BoskelleyCD, et al : An ovarian adenocarcinomaline derived from SV40, E-cadoherin induced mesenchymal to epithelial transition in human ovarian surface epithelium. Int J Cancer 85 : 430-437, 2000.

18) 津熊秀明, 北川貴子, 花井菜:癌罹患の動向-西暦2015年までの全国値推計-・癌の臨床 38 : 1-10, 1992.

P.56 掲載の参考文献

1) フリー百科辞典「ウィキペディア」

2) KF Rokitansky:Uber die sogenannten des uterus. Opelungendesuters Medizinischear Jarbucher deskaiserl. Konigl obsterreichischen erstates Wien 26 : 39-77, 1838.

3) 玉舎輝彦:骨盤腹膜を持いた造膣術. 産婦人科治療 72 : 889-896, 1996.

4) Tamaya T, et al:The use of peritoneum for vaginoplasty in 24 patients with congenital absence of the vagina. EJ Obstet Gynecogy Reproductive Biol 72 :79-81, 1991.

5) 玉舎輝彦:アンドロゲンの生物学的作用. ペリネイタルケア 196 : 537-541, 1997.

6) アーネスト・ミラー・ヘミングウェイ : キリマンジャロの雪 The Snows of Kilimanjaro. ヘミングウェイ全短編(2), 高見浩(翻訳), 新潮文庫, 1996.

P.62 掲載の参考文献

1) Sinha YN:Structural Variants of Prolactin:Occurrence and Physiological Significance. Endocr Rev 16 : 354-369, 1995.
pubmed

2) Handwerger S , et al:The Physiology of decidual prolactin and other decidual pituitary tissue. Endocr Rev 12 : 337-355, 1991.

3) Gala RR : Prolactin and growth horrnone in the regulation of lactation. Neuroendocinol 46 : 155-161, 1987.

4) Nicoll CS, et al:Evolutionally origins of prolactins growth hormones and placental lactogenic homone. Xxx. The primary stracture of the sheep hormone. Arch Biochem Biophys 141 : 705-737, 1970.

5) Hosino A, et al : Sexual dimorphism in prolactin. In : Ochiai K, et al (editors) , Endocrine Correlates of Reproduction. pp145-1216, Japan Scientific Societies Press, Tokyo, 1985.

6) Yazigi BA, et al : Prolactin disorders. Fertil Steril 67 : 215-225, 1997.

7) Frantz AG, et al : Endocrine disorders of the breast. Willson TJ, et al (editors) , Williams Textbook of Obstet 8ed, pp953-975, Philadelphia;BW Saunders Comp, 1992.

8) Boulanger CM, et al : Lack of tumor reduction in hyperprolactinemic women with extrasellar macroadenoma treated with bromocriptine. Fertil Steril 44 : 532-535, 1985.
pubmed

9) Johnston JM, et al : prospective longitudinal study of the oxitocin and prolactin in response to infant suckling in long-term lactation. J Clin Endocrinol Metab 62 : 6532-6537, 1986.

10) Faglia G, et al:Influence of previous bromocriptine therapy on surgery for microprolactinoma. Lancet 1 : 133-134, 1983.

11) Schlechte J, et al : Prolactin-secreting pituitary tumors. Endocr Rev 1 : 295-308, 1980.
pubmed

12) Cosman D, et al:A new cytokine receptor superfamily. Trends Bochem Sci 15 : 265-270, 1990.

13) Klibanski A, et al : Effects of prolactin and oestrogen deficiency in amenorreic boneloss. J Clin Endocri Metab 67 : 124-130, 1988.

14) ance ML, et al : prolactinoma. J Clin North Am 16 : 731-802, 1988.

15) Aisaka K, et al:Analysis of clinical backgrounds and pathogenesis of luteal phase defect. Horm Res 37 (Sppl 1) : 41-47, 1992

16) Mori O, et al:Effect of bromocriptine on prolactin-secreting pituitary adenoma. Cancer 66 : 230-238, 1985.

17) Synder PS, et al : Hypopituitalism follow ingradiation therapy of pituitary adenomas. Am J Med 81 : 457-462, 1986.

18) Serri O, et al : Recurrence of hyperprolactinemia after elective transphenoidal adenectomy in women with prolactinoma. N Engl Med 309 : 280-283, 1983.

19) Horvarth E, et al : Gonadotrophadenoma of the human pituitary ; sex related fine-structural dichotomy. A histrogic immunocytochemical, and electron-microscopic study of 30 tumors. Am J Pathol 117 : 429-440, 1984.

P.66 掲載の参考文献

1) Diarnanti-Kandarakis E : Controversies in endocrinology A modern medical Buandary : poly cystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metabo 88 : 1927-1932, 2003.

2) Cambell PJ, et al : Impact of obesity on insulin action in volunteers with normal glucose tolerance:demonstration of a threshold for the adverse effect of obesity. J Clin Endocrinol Metab 70 : 114-118, 1990.

3) The National Cholesterol Education Program Expert Pannel Executive Summary of the Third Report of the national cholesterol Education Program Expert Panel on detection : Evaluation,and treatment of high blood cholesterol in adults. [adult treatment Pannel 3]. JAMA 285 : 2486-2497, 2001.

4) Glueck CJ, et al:Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes : prospective longitu-dinal assessment of women with polycystic ovary syndrome from preconception throut pregnancy. Hum Reprod 19 : 510-521, 2004.

5) Homberg R : Should patients with PCOS with metoformin ? A note of cautiosoptimism. Hum Reprod 17 : 853-856, 2002.

6) Stadtnauer LA, et al:Shoud patients with PCOS be treated with metoformin benefits of insulin sensitizing drugs in PCOS-beyond ovulation induction. Hum Reprod 17 : 3016-3025, 2002.

P.68 掲載の参考文献

1) Azziz R : Editorial : Poycystic Ovary Syndrome, Insulin Resistance, and Molecular effects of Insulin Signaling. J Clin Endocrinol Metab 87 : 4085-4093, 2002.

2) Borona E, et al : Prevalence in polycystic ovarian syndrome. J Clin Endocrinol Metab 75 : 577-583, 1998.

3) Li M, et al : Decreased insulin receptor (IR) autophosphorylation in fibroblasts from patients with PCOS effects of serine inhibitors and IR activators. J Clin Endocrinol Metab 82 : 1421-1425, 1995.

4) Eki I, et al : Impaired adipocytes lipolysis in noneobese women with the polycystic ovary syndorome:a possible link to insulin resistance ? J Clin Endocrinol Metab 82 : 1147-1153, 1997.

5) Djursing H : Hypothramic-pituitary-gonadal function in ilsulin treated diabetic women with and without amenorrhea. Dan Med Bull 34 : 139-147, 1987.
pubmed

6) Djursing H, et al : Gonadotropin responses to gonadotropin-releasing hormone and prolactin responses to thyrotropin-releasing hormone and metoclopramidin women with insulin dependent diabetes mellitus (IDDM) . Acta Endocrinol (Copenh) 107 : 450-455, 1984.

P.75 掲載の参考文献

1) Zawazki JK, Dunaif A : Diagnostic criteria for polycystic ovary syndorome : towards a rational approach, In:Dunaif A, Givens JR, Haseitine FR, et al, eds. Polycystic ovary syndorome. pp377-384, Blackwell Scientific, Boston, 1992.

2) Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group:Revised 2003 con-sensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81 : 19-25, 2004.

3) Azziz R : Controversy in clinical endocrinology. Diagnosis of polycystic ovarian syndrome : The Rotterdam Criteria are premature. J Clin Endocriol Metab 91 : 781-785, 2006.

P.76 掲載の参考文献

4) Franks S:Controversy in clinical endocrinology. Diagnosis of polycystic ovarian syndorome:In defense of the Rotterdam criteria. J Clin Endocrinol Metab 91 : 786-789, 2006.

5) Carmina E:The spectrum of androgen excess disorders. Fertil Steril 85:1582-1585, 2006.
pubmed

6) Maroulis GB : Evaluation of hirsutism and hyperandrogenemia. Fertil Steril 36 : 273-305, 1981.
pubmed

7) Azziz R, Sanchez LA, Knochenhauer ES, et al : Androgen excess in women : experience with over 1,000 consecutive patients. J Clin Endocrinol Metab 89 : 453-462, 2004.

8) Carmina E, Longo RA, Rini GB, et al:Phenotypic variation in hyperandrogenic women influences the finding of abnormal metabolic and caｒdiovascular risk parameters. J Clin Endocrinol Metab 90 : 2545-2549, 2005.
pubmed

9) Caｒmina E, Rosato F, Janni A, et al : Relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinal Metab 91 : 2-6, 2006.

10) Azziz R, Carmina E, Sawaya ME : Idiopathic hirstim. Endocr Rev 21 : 347-362, 2000.
pubmed

11) Knochenhauer ES, Key TJ, Kahsar-Miller W, et al:Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastem USA:a prospective study. J Clin Endocrinol Metab 83 : 3078-3082, 1998.

12) Dunaif A : Insulin resistance and the polycytic ovary syndrome : mechanism and implications for pathogenesis. Endocr Rev 18 : 774-800, 1997.

13) Huber-Buckholz MM, Carey DG, Norman RJ:Restoration of reproductive potential by lifesｔyle modification in obese polycystic ovary syndrome:role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 84 : 1470-1474, 1999.

14) Camina E, Legro R, Stamets K, et al:Differences in body weight between American and Italian women with the polycytic ovary syndrome:influence of the diet. Hum Reprod 11 : 2289-2293, 2003.

15) Legro PS, Kunselman AR, Dodson WC, et al : Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerande in polycystic ovary syndrome : a prospective,controlled study in 254 affected woman. J Clin Endocrinol Metab 84 : 165-169, 1999.

16) Dahlgren E, Janson PO, Johansson S, et al : Polycystic ovary syndrome and risk for myocardial infarction evaluated from a risk factor model based on a prospective study of women. Acta Obstet Gynecol Scand 71 : 599-604, 1992.
pubmed

17) Legno RS, Kunselman AR, Dunaif A:Prebalance and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 117 : 607-613, 2001.

18) Wild RA : Long-term health consequences of PCOS. Hum Reprod Update 8 : 231-241, 2002.
pubmed

19) Hardiman P, Pillay OS, Atiomo W:Polycystic ovary syndorome and endometrial carcinoma. Lancet 361 : 302-312, 2003.

20) Moran LJ, Noakes M, Cliｆｔon PM, et al:Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycytic ovary syndrome. J Clin Endocrinol Metab 88 : 812-819, 2003.

21) Dumn CJ, Peters DH : Metformin : A review of its pharmacological properties and therapeutic uses in non-insulin dependent diabetes. Drugs 49 : 721-749, 1995.

22) Futterweit W : Polycystic ovary syndrome:Clinical perspectives and management. Obstet Gynecol Surv 54 : 403-413, 1999.
pubmed

23) Costello MF, Eden JA:A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil Steril 79 : 1-13, 2003.
pubmed

24) Haas DA, Carr BR, Attia GR : Effects of on body mass index, menstrual cyclicity ; and ovalation induction in women with polycystic ovary syndrome. Fertil Steril 79:469-481, 2003.

P.80 掲載の参考文献

1) Zawarzki JK, Dunaif A : Diagnostic criteria fbr polcyxystic ovaly syndrome : towards a rational approach. In Danaif A, Givens JR, Haseitine FR, et al (eds) , polycystic syndrome. Fertil Steril 81 : 19-25, 2004.

2) 玉舎輝彦 : Rotterdam (2003) のPCOS (polycystic ovary syndrorne) 診断クライテリアに寄せて. 産婦人科治療 94 : 1007-1017, 2004.

3) Xita N, Tsatsoulis A : Review : Fetal programming of polycystic ovary syndrome by androgen excess:Evidence from experimental, clinical and genetic association studies. J Clin Endocrinol Metab 91 : 1660-1666, 2006.
pubmed

4) Franks S, Charani N, Vaterwonh D, et al:The genetic hasis of polycystic ovary syndrome. Hum Reprod 12 : 2641-2648, 1997.

5) Xita N, Goorgious I, Tsatsoulis A : The genetic hasis of polycystic ovary syndrome. Eur J Endocrinol 147 : 717-725, 2002.

6) Abbott DH, Duwesic DH, Eisener JR, et al:Insights into the development of PCOS from studies prematally androgenized femal rhesus monkys. Trends Endocrinol Metab 9:42-67, 1997.

7) Mastovaros G, Koliopaulos C, Creatsas G:Androgen and lipid profiles in adolescents with PCOs who were treated with twofoｒnus of combined oral contraceptives. Fertil Steril 77 : 919-926, 2002.

P.90 掲載の参考文献

1) Casper RF, Mitwally MFM : Review : Aromatase inhibitors for ovulation induction. J Clin Endocrinol Metab 91 : 760-771, 2006.
pubmed

2) Cole PA, Robinson CH:Mechanism and inhibition of cytochrome P-450 aromatase. J Med Chem 33 : 2933-2944, 1990.
pubmed

3) Santen RJ, Manni A, Harvey H, et al:Endocｒine treatment of breast cancer in women. Endocr Rev 11 : 1-45, 1990.

4) Buzdar A, Howell A : Adbances in aromatase inhibition:clinical efficacy and tolerability in the treatment of breast cancer. Clin Cancer Res 7 : 2620-2635, 2001.

5) Winer EP, Hudis C, Burstein HJ, et al : American Society of Clinical Oncology technology assessment on the use of Ais as adjuvant therapy for women with hormone receptor positive breast cancer : status report 2002. J Clin Oncol 2015 : 3317-3327, 2002.

6) Mauras N, Lima J, Patel D, et al:Pharmacokinetics and dose finding of a potent AI, aromasin (exemestane), in young males. J Clin Endocrinol Metab 88 : 5951-5956, 2003.

7) Sioufi A, Gauducheau N, Pineau V, et al:Absolute bioavailability of letrozole in healthy post menopausal women. Biopharm Drug Dispos 18 : 779-789, 1997.

8) Anderson RA, Groome NP, Baird DT : Inhibin A and inhibin B in women with polycystic ovarian syndorome during treatment with FSH to induce mono-ovulation. Clin Endocrinol(Oxf) 48 : 577-584, 1998.

9) Weil SJ, Vendola K, Zhou J, et al:Androgen receptor gene expression in the primate ovary:cellular localization, regulation, and functional correlations. J Clin Endocrinol Metab 837 : 2479-5485, 1998.

10) Weil SJ, Vendola K, Zhou J, et al : Androgen and follicle-stimulating hormone interactions in primate ovarian follicle development. J Clin Endocrinol Metab 848 : 2951-2956, 1999.

11) Vendola K, Zhou J, Wang J, et al:Androgens promote oocyte insulin-like growth factor I expression and initiation of follicle development in the primate ovary. Biol Reprod 612 : 353-357, 1999.

12) Jakimiuk AJ, Weitsman SR, Brzechffa PR, et al:Aromatase mRNA expression in individual follicles from polycystic ovaries. Mol Hum Reprod 41 : 1-8, 1998.

13) Nirmala PB, Thampan RV : Ubiquitination of the rat uterine estrogen receptor dependence on estradiol. Biochem Biophys Res Commun 213 : 24-31, 1995.
pubmed

14) Rosenfeld CR, Roy T, Cox BE:Mechansims modulating estrogen-induced uterine vasodilation. Vascul Pharmacol 382 : 115-125, 2002.

15) Mitwally MFM, Casper RF : Use of an AI for induction of ovulation in patients with an indadequate response to clomiphene citrate. Fertil Steril 75 : 305-309, 2000.

16) Sammour A, Biljan MM, Tan SL, et al:Prospective randomized trial comparing the effects of letrozole(LE)and clomiphene citrate(CC)on follicular development, endometrial thickness and pregnancy rate in patients undergoing super-ovulation prior to intrauterine insemination(IUI). Fertil Steri 76 : S110, 2001.

17) Al-Fozan H, Al-Khadouri M, Tan SL, et al : A randomized trial of letrozole versus clomiphene citrate in women undergoing superovulation. Fertil Steril 82 : 1561-1563, 2004.
pubmed

18) Al-Omari WR, Sulaiman WR, Al Hadithi N : Comparison of two Ais in women with clomiphene-resistant polycystic ovary syndrome. Int J Gynecol Obstet 853 : 289-291, 2004.

19) Ligibel JA, Winer EP : Clinical differences among the Ais. Clin Cancer Res 91 : 473S-479S, 2003.

20) Mitwally MF, Casper RF:Aromatase inhibition reduces the dose of gonadotropin required for controlled ovarian hyperstimulation. J Soc Gynecol Inverstig 11 : 406-415, 2004.
pubmed

21) Mitwally MF, Casper RF : Aromatase inhibition reduces gonadotropin dose reguired for controlled ovarian stimulation in women with unexplained infertility. Hum Reprod 188 : 158-1597, 2003.

22) Mitwally MF, Casper RF : Aromatase inhibition improves ovarian response to follicle-stimu-lating hormone in poor responders. Fertil Steril 774 : 776-780, 2002.

23) Biljan MM, Tan SL, Tulandi T : Prospective randomized trial comparing the effects of 2.5 and 5.0 mg of letrozale(LE)on follicular development, endometrial thickness and pregnancy rate in patients undergoing superovulation. Fertil Steril 806 : 1325-1329, 2003.

24) Goss PE : Risks versus benefits in the clinical application of Ais. Endocr Relat Cancer 6 : 325-332, 1999.

25) Schoot DC, Coelingh BHJ, Mannaerts BM, et al:Human recombinant FSH induced growth of preovulatory follicle without concomitant increase in androgen and estrogen biosynthsis in a woman with isolated GT deficiency. J Clin Endocrinol Metab 74 : 1471-1473, 1992.

26) Simon C, Cano F, Valbuena D, et al:Clinical evidence for a detrimental effect on uterine receptivity of high serum E2 concentrations in high and normal responder patients. Hum Reprod 10 : 2432-2437, 1995.

27) Valbuena D, Martin J, de Pablo JL, et al : Increasing levels of estradiol are deleterious to embryonic emplantion because they directy affect the embryo. Fertil Steril 765 : 962-968, 2001.

28) Simon C, Garcia VJJ, Valbuena D, et al:Increasing uterine receptivity by decreaseing estradiol levels during the preimplantation period in high responders with the use of a follicle-stimulating hormone stepdown regimen. Fertil Steril 70 : 234-239, 1998.

29) Goswami SK, Das T, Chattopadhyay R, et al : A randomized single-blind controlled trial of letrozole as a low-cost IVF protocol in women with poor ovarian response:a preliminary report. Hum Reprod 19 : 2031-2035, 2004.

30) Garcia-Velasco JA, Moreno L, Pacheco A, et al : the AI letrozole increase the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients:a pilot study. Fertil Steril 84 : 82-27, 2005.

31) Oktay K, Buynk E, Libertella N, et al : Fertility preservation in breast cancer patients : a prospective contro lled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 23 : 4347-4353, 2005.

32) Mitwally MF, Biljan MM, Casper RE:Pregnccy outcome after the use of an AI for induction of ovulation. Am J Obstet Gynecol 192 : 381-386, 2005.

33) Al-Fadhli R, Sylvestre C, Buckett W, et al:A randomized trial of superovulation with two different doses of letrozole. Fertil Steril 85 : 161-164, 2006.
pubmed

34) Tiboni GM : AIs and teratogenesis. Fertil Steril 81 : 1158-1159, 2004.

35) Biljan MM, Hemmings R, Brassard N : The outcome of 150 babies following the treatment with letrozole or letrozole and gonadotoropins. Fertil Steril 84 (Suppl 1) : S95, 2005.

36) Tulandi T, Martin J, Al-Fadhi R, et al : Fertil Steril 85 : 1761-1765, 2006.

P.94 掲載の参考文献

1) Erian J : Assessment of medical treatments for menorrhagia. Brit J Obstet Gynecol 11 (Suppl) : 15-18, 1994.

P.96 掲載の参考文献

1) Polivy J : Dieting and bingeing a casal analysis. Am J Psychol 40 : 193-201, 1985.

2) Dye T, et al Mensrual cycle and appetite control ; implication for weight regulation. Hum Reprod 12 : 1192-1151, 1997.

3) Gold JM : Historical perspective of premenstrual syndrome. In Gold JM et al (eds) In Realities Dysphorias myths and realities. Am Psychiatric Association, New York, 1994.

4) Marsden PJ, et al : Adipocyte insulinaction during ｔhe normal menstrual cycle. Hum Reprod 11 : 968-974, 1996.

はじめての方へ

個人／法人会員登録のご案内